Identity
- Security key
- 19203
- Ticker
- NKTX
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2020-07-10
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- NKTX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $171,183,250.49
- Shares outstanding (class)
- 71,545,358
- Shares outstanding (weighted)
- 71,624,791
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 106
- Location
- SOUTH SAN FRANCISCO, CA
- Homepage
- https://www.nkartatx.com
- Description
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
Market cap and share counts drift.